Metformin regulates TRPM6, a potential explanation for magnesium imbalance in type 2 diabetes patients.

Metformin therapy is associated with lower serum magnesium (Mg) levels in type 2 diabetes patients. The TRPM6 channel determines the fine-tuning of Mg (re)absorption in intestine and kidney. Therefore, we aimed to investigate the short- and long-term effects of metformin on TRPM6.

Diabetes-induced hypomagnesemia is not modulated by metformin treatment in mice.

Approximately 30% of patients with type 2 diabetes mellitus (T2D) have hypomagnesemia (blood magnesium (Mg) concentration <0.7 mmol/L). In T2D patients, treatment with metformin is associated with reduced blood Mg levels.

Determinants of hypomagnesemia in patients with type 2 diabetes mellitus.

Background: Hypomagnesemia (plasma magnesium (Mg) concentration <0.7 mmol/L) has been described in patients with type 2 diabetes. Polypharmacy is inevitable when treating a complex disease such as type 2 diabetes and could explain disturbances in the plasma Mg concentration.